Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIV V1V2 mRNA-LNP vaccine
- Development stage
- Preclinical
- Lead developer
- Icahn School of Medicine
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
The HIV V1V2 mRNA-LNP vaccine is a preclinical lipid nanoparticle-encapsulated mRNA (mRNA-LNP) vaccine candidate designed to prevent HIV-1 infection. Developed through a collaboration involving the Icahn School of Medicine at Mount Sinai, the University of Pennsylvania, Oregon Health and Science University, and Acuitas Therapeutics, the vaccine encodes the V1V2 domain of the CRF_01.AE244 strain of the HIV-1 envelope glycoprotein gp120 on a trimeric 2J9C scaffold. The V1V2 domain is a key target for antibodies associated with a reduced risk of HIV-1 infection. Preclinical evaluations in mice and rhesus macaques have demonstrated that the vaccine is highly immunogenic, eliciting robust, cross-clade functional antibody responses capable of recognizing native envelope proteins and mediating Fc-dependent effector functions, such as antibody-dependent cellular phagocytosis (ADCP).
- Other names
- HIV V1V2 mRNA-LNPV1V2 mRNA-LNPV-1V2 mRNA-LNPV 1V2 mRNA-LNPV1V2 mRNA-LNP vaccineV-1V2 mRNA-LNP vaccineV 1V2 mRNA-LNP vaccine
02
Targets
CCR5 (C-C chemokine receptor type 5)CD4 (T lymphocyte surface antigen)CXCR4 (C-X-C motif chemokine receptor 4)C1Q (Complement C1q)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)TLR4 (Toll-like receptor 4)gp120 (HIV-1 envelope glycoprotein (gp120/gp41) epitopes)
Beyond the preview
Go deeper on HIV V1V2 mRNA-LNP vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIV V1V2 mRNA-LNP vaccine.